ASSURE: An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)

Brief description of study

The purpose of this research study is to evaluate the long-term safety and tolerability of seladelpar in treating PBC patients. Primary Biliary cholangitis (PBC) is a serious, rare slowly progressive and potentially life – limiting autoimmune liver disease which impairs bile flow in the liver and results in liver injury and possible liver failure. This will be done by looking at how the drug affects PBC. Seladelpar is an investigational drug. Investigational means that the drug has not been approved by the United States Food and Drug Administration (FDA).

Clinical Study Identifier: s20-01566 Identifier: NCT03301506
Principal Investigator: Ira M. Jacobson.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.